阿苯达唑在棘球蚴病治疗中的安全性分析

Analysis on safety of albendazole in the treatment of echinococcosis

分析阿苯达唑在棘球蚴病治疗中发生各种不良反应的概率,探讨阿苯达唑在棘球蚴病治疗中的安全性,为临床安全用药提供参考。通过PubMed、EmBase、中国生物医学文献数据库、中国期刊全文数据库和万方数据库检索(检索时间为各个数据库建库开始至2019年9月),收集阿苯达唑用于棘球蚴病治疗的文献,参照纳入与排除标准,对文献中阿苯达唑用药后发生的药物不良反应进行统计分析。共纳入26篇文献,结果显示研究地区以我国新疆为主,西藏地区对该药物的研究相对缺乏,有限的研究文献中严重不良反应发生率不高,不良反应类型常见于消化系统、皮疹、血液系统等,且多为一过性。提示目前关于阿苯达唑在棘球蚴病治疗中的不良反应发生研究有限,虽然基于现有研究提示阿苯达唑治疗有一定的安全性,但仍需更多大规模临床试验的验证和支撑。

This study aimed to investigate the probability of adverse effects of albendazole in the treatment of echinococcosis and assess the drug safety,providing reference for its safe medication in clinical practice.Literature search was performed in PubMed,EMBase,China Biology Medicine disc(CBMdisc),China National Knowledge Infrastructure(CNKI)and Wanfang Databases to obtain studies on the use of albendazole in the treatment of echinococcosis.Eligible studies were included according to the inclusion and exclusion criteria,and the reported adverse effects of albendazole were statistically analyzed.This review analyzed 26 eligible studies included,and found that the studies were mostly performed in Xinjiang,while considerably fewer performed in Tibet.According to the literature available,the occurrence rate of severe adverse effects was not high,and the adverse effects often involved digestive system,skin rash,and blood system,with transient presentation in most cases.The data indicates that the studies on the adverse side effects of albendazole is apparently limited.Although the current study results currently available suggest that albendazole is rather safe in clinical use,scale-up clinical trials remain imperative to verify this safety and address the drug safety.